相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Efficacy and safety of anagrelide as a first-line drug in cytoreductive treatment-naive essential thrombocythemia patients in a real-world setting
Tomoki Ito et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2019)
Treatment of essential thrombocythemia in Europe: a prospective long-term observational study of 3649 high-risk patients in the Evaluation of Anagrelide Efficacy and Long-term Safety study
Gunnar Birgegard et al.
HAEMATOLOGICA (2018)
Treatment of essential thrombocythemia in Europe: a prospective long-term observational study of 3649 high-risk patients in the Evaluation of Anagrelide Efficacy and Long-term Safety study
Gunnar Birgegard et al.
HAEMATOLOGICA (2018)
A Case of Anagrelide-Induced Nonischemic Cardiomyopathy in a Patient With Essential Thrombocythemia
Pritpal Singh
JOURNAL OF PHARMACY PRACTICE (2018)
Anagrelide treatment and cardiovascular monitoring in essential thrombocythemia. A prospective observational study
Giovanni Tortorella et al.
LEUKEMIA RESEARCH (2015)
Reversible dilated cardiomyopathy associated with long-term anagrelide therapy in a patient with chronic myeloproliferative disease: A serial 2-dimensional speckle tracking echocardiographic study
Sun Hwa Lee et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2014)
Phase III, single-arm study investigating the efficacy, safety, and tolerability of anagrelide as a second-line treatment in high-risk Japanese patients with essential thrombocythemia
Yuzuru Kanakura et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2014)
Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET Study, a randomized controlled trial
Heinz Gisslinger et al.
BLOOD (2013)
Open-label, dose-titration and continuation study to assess efficacy, safety, and pharmacokinetics of anagrelide in treatment-naive Japanese patients with essential thrombocythemia
Shinichiro Okamoto et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2013)
Cytoreductive treatment patterns for essential thrombocythemia in Europe. Analysis of 3643 patients in the EXELS study
Carlos Besses et al.
LEUKEMIA RESEARCH (2013)
Inverted takotsubo cardiomyopathy in a patient with essential thrombocythemia exposed to anagrelide and phentermine
Artur Dziewierz et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2012)
Peripheral edema associated with calcium channel blockers: incidence and withdrawal rate - a meta-analysis of randomized trials
Harikrishna Makani et al.
JOURNAL OF HYPERTENSION (2011)
Low impact of cardiovascular adverse events on anagrelide treatment discontinuation in a cohort of 232 patients with essential thrombocythemia
Luigi Gugliotta et al.
LEUKEMIA RESEARCH (2011)
Anagrelide represses GATA-1 and FOG-1 expression without interfering with thrombopoietin receptor signal transduction
M. Ahluwalia et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2010)
Atypical Takotsubo syndrome during anagrelide therapy
Riccardo Proietti et al.
JOURNAL OF CARDIOVASCULAR MEDICINE (2009)
Successful rechallenge with anagrelide in a patient with anagrelide-associated cardiomyopathy
Raymond S. M. Wong et al.
ANNALS OF HEMATOLOGY (2008)
High-output heart failure associated with anagrelide therapy for essential thrombocytosis
P Engel et al.
ANNALS OF INTERNAL MEDICINE (2005)
Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia
CN Harrison et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Anagrelide: analysis of long-term efficacy, safety and leukemogenic potential in myeloproliferative disorders
SM Fruchtman et al.
LEUKEMIA RESEARCH (2005)
Anagrelide-associated cardiomyopathy in polycythemia vera and essential thrombocythemia
DJ Jurgens et al.
BLOOD (2004)
Long-term use of anagrelide in young patients with essential thrombocythemia
EC Storen et al.
BLOOD (2001)
分享论文
